CASP14

Across TCGA pan-cancer cohorts, CASP14 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CASP14 data layer compared with 19 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CASP14 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CASP14 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC and LSCC are the cancer types where CASP14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.305	1.000	.017	9	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.856	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CASP14–PDAC (DFS)

Open the PDAC breakdown →